Document is current
Any future updates will be listed below
-
Authors
Pagès-Gallego, Marc https://orcid.org/0000-0001-8888-5699
van Soest, Daan M. K. https://orcid.org/0000-0002-6330-0428
Besselink, Nicolle J. M. https://orcid.org/0000-0002-8961-4441
Straver, Roy https://orcid.org/0000-0002-8031-1735
Keijer, Janneke P. https://orcid.org/0000-0003-2422-2495
Vermeulen, Carlo https://orcid.org/0000-0003-0412-5313
Marcozzi, Alessio https://orcid.org/0000-0001-7477-3661
van Roosmalen, Markus J. https://orcid.org/0000-0003-3329-1185
van Boxtel, Ruben https://orcid.org/0000-0003-1285-2836
Burgering, Boudewijn M. T. https://orcid.org/0000-0002-4044-9596
Dansen, Tobias B. https://orcid.org/0000-0001-5259-8815
de Ridder, Jeroen https://orcid.org/0000-0002-0828-3477
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (Oncode Institute Base Fund, 14798)
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 21 May 2025
First Online: 5 June 2025
Competing interests
: J.d. R. and A.M. are co-founders and directors of Cyclomics, a genomics company, they declare no competing interests. M.P-G., D.M.K.v.S., N.J.M.B., R.S., J.P.K., C.V., M.J.v.R., R.v.B., B.M.T.B., and T.B.D. declare no competing interests.
